Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
TISSIUM logo — Biomorphic Programmable Polymers

TISSIUM

Biomorphic Programmable Polymers

Founded 2013 France France 132 employees Series D Total: $215.20M Biotechnology, Health Care +1

General Information

Company Name TISSIUM
Founded Year 2013
Location France France +3
Employees 132
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Series D
Social

Get notified when TISSIUM moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About TISSIUM

TISSIUM is a biotechnology startup with the slogan "Biomorphic Programmable Polymers," initially established in 2013 in France. The company's core objective is to address the persistent medical challenge of tissue reconstruction and restoration of natural function. Their groundbreaking technology, first discovered at the labs of Bob Langer and Jeff Karp at MIT, has the potential to revolutionize tissue reconstruction across various therapeutic areas. TISSIUM's unique product development approach revolves around proprietary polymers, activation technologies, and delivery devices. Moreover, they have established an integrated platform for innovation, design, commercialization, and manufacturing to support internal programs and co-development partnerships with medtech industry leaders. Notably, the company received a significant €50.00M Series D investment on 23 May 2023, with key investors including Sofinnova Partners, Crédit Mutuel Innovation, Mérieux Equity Partners, Cathay Health, and Fonds Stratégique d'Investissement.

Taxonomy: Medical Device, MedTech, Synthetic Polymers, Tissue Reconstruction, Biodegradable Sealants, Wound Closure, Minimally Invasive Surgery, Innovation, Research and Development, Biomedical Engineering, Biomedical Materials, Polymer Science, Surgical Adhesives, Biomedical Innovation

Services & Products

development and production of biomorphic programmable polymers for tissue reconstruction

Target Customers

healthcare institutions surgeons medical professionals

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Series D €30.00M 5 Mérieux Développement, Cathay +3 24 Jun 2026
Series D €50.00M 5
Sofinnova Partners Crédit Mutuel Innovation Mérieux Equity Partners Cathay Health Fonds Stratégique d'Investissement
23 May 2023
Series C €50.00M 2
Sofinnova Partners Cathay Capital
31 Aug 2021
Debt Financing $7.00M 3
Bpifrance BNP Paribas CM-CIC Capital Prive
01 Oct 2020
Venture Round Unknown 1 IBD Ventures 11 Feb 2020

View All 11 Funding Rounds

Latest News

View All
FDA clears path for Paris startup TISSIUM's tissue reconstruction without sutures, redefining surgic... — Tech
FDA clears path for Paris startup TISSIUM's tissue reconstruction without sutures, redefining surgical standards
Tech Jun 27, 2025
Tissium raises €30M in equity funding, €30M in debt — Tech
Tissium raises €30M in equity funding, €30M in debt
Tech Jun 24, 2026
Tissium raises €60M to take its sutureless nerve glue to the US — Thenextweb
Tissium raises €60M to take its sutureless nerve glue to the US
Thenextweb Jun 24, 2026

TISSIUM Alternatives & Competitors

View All Alternatives
TISSIUM vs
POLIMERBIO
POLIMERBIO Spain

"A new generation of biodegradable polymer-based medical devices"

Seed
15 employees
Biotechnology
Compare TISSIUM vs POLIMERBIO
TISSIUM vs
Cell Tissue Technology Sdn Bhd
Cell Tissue Technology Sdn Bhd Malaysia

Empowering Medical Innovation

Series Unknown
19 employees
Biotechnology, Pharmaceutical
Compare TISSIUM vs Cell Tissue Technology Sdn Bhd
TISSIUM vs
BioTherapeutics Inc.
BioTherapeutics Inc. United States

Innovative small-molecule drugs for inflammation in autoimmune disorders and type 2 diabetes.

Grant
4 employees
Biotechnology, Health Care
Compare TISSIUM vs BioTherapeutics Inc.
View all alternatives

FAQ About TISSIUM

Biomorphic Programmable Polymers
TISSIUM was founded in 2013.
TISSIUM is headquartered in France.
TISSIUM operates in the following industries: Biotechnology, Health Care, Medical Devices.
TISSIUM has approximately 132 employees.
TISSIUM has completed 11 funding rounds, raising a total of $215.20M. The latest funding stage is Series D.
TISSIUM offers: development and production of biomorphic programmable polymers for tissue reconstruction.
Top alternatives and competitors to TISSIUM include POLIMERBIO, Cell Tissue Technology Sdn Bhd, BioTherapeutics Inc., Profusa, Alivio Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TISSIUM and POLIMERBIO are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors TISSIUM and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy